Enroll the first subject in the BEACON-101 clinical trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Feb 2022
- Due
- 31 Dec 2022
- Delivered
- November 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Enroll the first subject in the Phase 1/2 clinical trial of BEAM-101 for the treatment of SCD, which is referred to as the BEACON-101 trial, in the second half of 2022”
What we found
Evidence strength A What the grades mean
The company announced in November 2022 that it had enrolled the first patient in the BEACON clinical trial, meeting the commitment to enroll the first subject in the second half of 2022.
-
A Beam Therapeutics Inc. 10-K filed 2023-02-28
“In November 2022, we announced that we enrolled the first patient in our Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-101 for the treatment of sickle cell disease, which we refer to as our BEACON trial.” ✓ confirmed on the page
Market reaction: the shares moved -0.5% against the S&P 500 over the three sessions around the disclosure (27 Feb 2023 to 2 Mar 2023). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 28 Feb 2022
Deadline 31 Dec 2022 (“in the second half of 2022”)
-
Version 2 · stated 9 May 2022
Deadline 31 Dec 2022 (“in the second half of 2022”) · wording expected
“expects to enroll the first patient in its Phase 1/2 clinical trial evaluating the safety and efficacy of BEAM-101 for the treatment of SCD, referred to as the BEACON-101 trial, in the second half of”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Enroll
- Deliverable
- BEACON-101 clinical trial enrollment
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-BEAM-003205 · Corrections policy